Jeb has more than 20 years of leadership experience delivering operational excellence in the biotechnology industry. He joins KalVista from AVEO Oncology, and LG Chem Company, where he was the Chief Operating Officer and responsible for multiple business and technical functions at a commercial stage organization. During his time at AVEO, he successfully helped to lead the integration processes with LG Chem following the acquisition of AVEO. Previously, he served at Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as Chief Operating Officer responsible for key business operations leading to the U.S. FDA approval of RETHYMIC®, the first tissue based therapy approved under the RMAT program. Prior to Enzyvant, Jeb served in Chief Operating Officer roles at Compass Therapeutics and Horizon Discovery Group where he was responsible for leading operations at both organizations through several increases in scale. Jeb holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.
